vs
Side-by-side financial comparison of AIM ImmunoTech Inc. (AIM) and Aligos Therapeutics, Inc. (ALGS). Click either name above to swap in a different company.
Aligos Therapeutics, Inc. is the larger business by last-quarter revenue ($169.0K vs $21.0K, roughly 8.0× AIM ImmunoTech Inc.). Aligos Therapeutics, Inc. runs the higher net margin — -11763.9% vs -19881.0%, a 8117.0% gap on every dollar of revenue. On growth, AIM ImmunoTech Inc. posted the faster year-over-year revenue change (-53.3% vs -72.1%). Over the past eight quarters, AIM ImmunoTech Inc.'s revenue compounded faster (-27.5% CAGR vs -50.7%).
AIM ImmunoTech Inc., formerly known as Hemispherx Biopharma Inc., is a biopharmaceutical company based in Ocala, Florida that is focused on the research and development of therapeutics to treat multiple types of cancers, various viruses and immune-deficiency disorders. Founded in 1990, the company has twenty-three employees.
Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel targeted therapies for prevalent liver diseases and viral infections. Its core pipeline includes candidates for chronic hepatitis B, non-alcoholic steatohepatitis, and other liver-related disorders, advancing R&D to serve unmet global patient needs.
AIM vs ALGS — Head-to-Head
Income Statement — Q4 2025 vs Q4 2025
| Metric | | |
|---|---|---|
| Revenue | $21.0K | $169.0K |
| Net Profit | $-4.2M | $-19.9M |
| Gross Margin | — | — |
| Operating Margin | -14057.1% | -12907.7% |
| Net Margin | -19881.0% | -11763.9% |
| Revenue YoY | -53.3% | -72.1% |
| Net Profit YoY | 30.0% | 75.8% |
| EPS (diluted) | $-6.46 | $4.23 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $21.0K | $169.0K | ||
| Q3 25 | $26.0K | $741.0K | ||
| Q2 25 | $25.0K | $965.0K | ||
| Q1 25 | $16.0K | $311.0K | ||
| Q4 24 | $45.0K | $606.0K | ||
| Q3 24 | $35.0K | $1.3M | ||
| Q2 24 | $50.0K | $1.1M | ||
| Q1 24 | $40.0K | $694.0K |
| Q4 25 | $-4.2M | $-19.9M | ||
| Q3 25 | $-3.3M | $-31.5M | ||
| Q2 25 | $-2.8M | $-15.9M | ||
| Q1 25 | $-3.7M | $43.1M | ||
| Q4 24 | $-6.0M | $-82.2M | ||
| Q3 24 | $-3.7M | $-19.3M | ||
| Q2 24 | $-1.8M | $5.1M | ||
| Q1 24 | $-5.8M | $-34.9M |
| Q4 25 | -14057.1% | -12907.7% | ||
| Q3 25 | -9411.5% | -3827.4% | ||
| Q2 25 | -10584.0% | -1924.0% | ||
| Q1 25 | -22618.8% | -6187.5% | ||
| Q4 24 | -13011.1% | -3393.2% | ||
| Q3 24 | -12825.7% | -1610.5% | ||
| Q2 24 | -7388.0% | -2489.5% | ||
| Q1 24 | -14335.0% | -3176.7% |
| Q4 25 | -19881.0% | -11763.9% | ||
| Q3 25 | -12630.8% | -4256.0% | ||
| Q2 25 | -11176.0% | -1643.8% | ||
| Q1 25 | -23156.3% | 13854.7% | ||
| Q4 24 | -13260.0% | -13556.1% | ||
| Q3 24 | -10571.4% | -1540.7% | ||
| Q2 24 | -3672.0% | 477.0% | ||
| Q1 24 | -14542.5% | -5023.5% |
| Q4 25 | $-6.46 | $4.23 | ||
| Q3 25 | $1.57 | $-3.04 | ||
| Q2 25 | $-3.68 | $-1.53 | ||
| Q1 25 | $-0.05 | $-2.11 | ||
| Q4 24 | $-21.80 | $-13.10 | ||
| Q3 24 | $-6.00 | $-3.07 | ||
| Q2 24 | $-3.00 | $0.81 | ||
| Q1 24 | $-0.12 | $-5.58 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $3.0M | $77.8M |
| Total DebtLower is stronger | $4.5M | — |
| Stockholders' EquityBook value | $-9.8M | $53.5M |
| Total Assets | $5.8M | $88.5M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $3.0M | $77.8M | ||
| Q3 25 | $2.4M | $99.1M | ||
| Q2 25 | $835.0K | $122.9M | ||
| Q1 25 | $2.2M | $137.9M | ||
| Q4 24 | $4.0M | $56.9M | ||
| Q3 24 | $7.2M | $74.9M | ||
| Q2 24 | $10.1M | $94.5M | ||
| Q1 24 | $10.9M | $112.7M |
| Q4 25 | $4.5M | — | ||
| Q3 25 | — | — | ||
| Q2 25 | $2.7M | — | ||
| Q1 25 | $2.4M | — | ||
| Q4 24 | $2.8M | — | ||
| Q3 24 | $3.3M | — | ||
| Q2 24 | $3.3M | — | ||
| Q1 24 | $3.3M | — |
| Q4 25 | $-9.8M | $53.5M | ||
| Q3 25 | $-6.1M | $71.8M | ||
| Q2 25 | $-6.5M | $101.9M | ||
| Q1 25 | $-3.9M | $116.4M | ||
| Q4 24 | $-1.3M | $-29.0M | ||
| Q3 24 | $2.9M | $50.1M | ||
| Q2 24 | $6.1M | $67.2M | ||
| Q1 24 | $4.8M | $59.8M |
| Q4 25 | $5.8M | $88.5M | ||
| Q3 25 | $5.5M | $109.8M | ||
| Q2 25 | $4.1M | $134.7M | ||
| Q1 25 | $6.2M | $150.7M | ||
| Q4 24 | $8.6M | $70.1M | ||
| Q3 24 | $13.6M | $88.4M | ||
| Q2 24 | $15.7M | $108.8M | ||
| Q1 24 | $16.2M | $127.9M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 1.13× | — | ||
| Q2 24 | 0.54× | — | ||
| Q1 24 | 0.69× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-2.0M | $-21.7M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-2.0M | $-21.7M | ||
| Q3 25 | $-5.1M | $-24.3M | ||
| Q2 25 | $-1.5M | $-15.5M | ||
| Q1 25 | $-2.4M | $-20.9M | ||
| Q4 24 | $-4.0M | $-18.4M | ||
| Q3 24 | $-3.1M | $-20.1M | ||
| Q2 24 | $-3.0M | $-19.5M | ||
| Q1 24 | $-4.8M | $-22.7M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | -0.49× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | -3.85× | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
